AI
| Followers | 843 |
| Posts | 122988 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Monday, December 24, 2007 3:11:20 PM
MNTA – Thanks, Jon, for your feedback. Your numbers are lower than mine across the board, so maybe should ought to drink more eggnog!
>Case 1 Odds 10% (price $35 as you will never know that TEVA/Ampha got denied so always will be a discount)<
Actually, investors will know with near certainty whether Teva and Amphastar get approval for generic Lovenox. How will we know? I’ll make this a quiz
>E. Disagree - actually agree as I think odds are ONLY one in three.<
You aren’t really agreeing or disagreeing because I didn’t hazard a guess as to whether MNTA will be bought out in 2008. Rather, I assumed MNTA will not be bought in order to simplify the case-by-case valuation analysis. Regards, Dew
>Case 1 Odds 10% (price $35 as you will never know that TEVA/Ampha got denied so always will be a discount)<
Actually, investors will know with near certainty whether Teva and Amphastar get approval for generic Lovenox. How will we know? I’ll make this a quiz
>E. Disagree - actually agree as I think odds are ONLY one in three.<
You aren’t really agreeing or disagreeing because I didn’t hazard a guess as to whether MNTA will be bought out in 2008. Rather, I assumed MNTA will not be bought in order to simplify the case-by-case valuation analysis. Regards, Dew
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Where Real Traders Talk Markets
Join thousands of traders sharing insights, catalysts, and charts.
